Early Post-marketing Study of Eliquis (Apixaban)

Bristol-Myers Squibb

Overview

The primary objective of the study is to identify and describe any suspected (AEs) in all patients with NVAF treated with Apixaban, as a request of the National Center of Pharmacovigilance (CNFV) in Mexico.

Study Type

OBSERVATIONAL

Conditions

Non-valvular Atrial Fibrillation (NVAF)

Interventions

ApixabanDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * All patients with NVAF at the sentinel site for the CNFV in Mexico who received at least 1 dose of Apixaban to reduce the risk of stroke or systemic embolism during the specified 24-month study period Exclusion Criteria: * Subjects who received Apixaban as part of a clinical trial * Subjects who received Apixaban for any indication other than local approval (ie, to reduce the risk of stroke and systemic embolism in patients with NVAF)

Locations (2)

Local Institution

Guadalajara, Jalisco, Mexico

Local Institution

Puebla City, Puebla, Mexico

Outcomes

Primary Outcomes

Determine the reporting rate of on-treatment adverse events (AEs) by the treating physicians

Time frame: Up to 24 month study period

Identify, describe, and report any suspected AEs that occur while on treatment with Apixaban or preventing stroke and systemic embolism in patients with NVAF

Time frame: Up to 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.